PTC299
- Generic Name
- PTC299
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 053QD2I96A
- Background
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 189
- Registration Number
- NCT04439071
- Locations
- 🇺🇸
University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States
🇨🇴Fundación Santa Fe de Bogotá, Bogotá, Colombia
🇧🇪Clinique Saint Pierre, Ottignies, Belgium
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03761069
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸SCRI Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Rochester MC, Rochester, New York, United States
PTC299 for Treatment of Neurofibromatosis Type 2
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 11
- Registration Number
- NCT00911248
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
PTC299 for Treatment of Advanced Cancer
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT00704821
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT00508586
- Locations
- 🇺🇸
New York University Clinical Cancer Center, New York, New York, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.